Fluconazole in hypercalciuric patients with increased 1,25(OH)₂D levels: the prospective, randomized, placebo-controlled, double-blind FLUCOLITH trial.

ABSTRACT:

Background

Hypercalciuria is one of the most frequent metabolic disorders associated with nephrolithiasis and/or nephrocalcinosis possibly leading to chronic kidney disease (CKD) and bone complications in adults. Orphan diseases with different underlying primary pathophysiology share inappropriately increased 1,25(OH)₂D levels and hypercalciuria, e.g., hypersensitivity to vitamin D and renal phosphate wasting. Their management is challenging, typically based on hyperhydration and dietary advice. The antifungal azoles are known to inhibit the 1α-hydroxylase and therefore decrease 1,25(OH)₂D levels; they are commonly used, with well described pharmacokinetic and tolerability data. Fluconazole has been successfully reported to reduce calciuria in patients with CY

SUBMITTER: Bertholet-Thomas A 

PROVIDER: S-EPMC9204961 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature